Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) was named winner of the 2025 BioTech Breakthrough Award for Cell Therapy Innovation of the Year on November 7, 2025. The company was recognized for its work developing gene and cell therapies using a patented secreted form of the human Klotho gene (s-KL) targeting neurodegenerative and age-related diseases including ALS, Alzheimer’s, and Parkinson’s.

The award highlights Klotho’s focus on therapies that aim to address neuronal aging and deliver durable, disease-modifying benefits.

NEW YORK, Nov. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO ) (the "Company" or "Klotho"), a U.S.-based biogenetics company, announces it has been selected as winner of the Fifth Annual BioTech Breakthrough Award in the "Cell Therapy Innovation of the Year" category.

Klotho Neurosciences earned this recognition for its pioneering work developing transformative gene and cell therapies using a patented, secreted form of the human Klotho gene (s-KL) to address devastating neurodegenerative and age-related diseases, including ALS, Alzheimer's disease, and Parkinson's disease. By targeting the underlying mechanisms of neuronal aging, Klotho's therapies aim to slow, halt, or reverse disease progression, offering durable, disease-modifying benefits for patients with conditions that currently have limited treatment options.

"This award highlights our commitment to translating cutting-edge scientific discoveries into meaningful therapies for patients suffering from neurodegenerative and age-related diseases," said Dr. Joseph Sinkule, Klotho Neurosciences' CEO. "As the global population ages, the need for therapies that address the root causes of age-related conditions has never been greater. Klotho's focus on the human Klotho protein positions us to meet this challenge, developing therapies that not only target neurodegeneration but also have the potential to improve health span and reduce the burden of age-related disease worldwide."

The BioTech Breakthrough Awards program recognizes the most innovative companies, technologies, and products in the global life sciences and biotechnology industries. Conducted annually by BioTech Breakthrough, a leading independent market intelligence organization, the awards celebrate excellence across biopharma, therapeutics, genomics, diagnostics, and research tools.

About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease.

Investor Contact and Corporate Communications:

Jeffrey LeBlanc, CFO
ir@klothoneuro.com

Website: www.klothoneuro.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-wins-the-2025-biotech-breakthrough-cell-therapy-innovation-of-the-year-award-302608758.html

SOURCE Klotho Neurosciences, Inc.

FAQ

What award did Klotho Neurosciences (KLTO) win on November 7, 2025?

Klotho Neurosciences won the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' award.

Why did KLTO receive the BioTech Breakthrough cell therapy award in 2025?

The company was recognized for developing gene and cell therapies using a patented secreted Klotho (s-KL) approach targeting neurodegenerative and age-related diseases.

Which diseases does Klotho Neurosciences target with its s-KL therapies?

Klotho’s programs focus on ALS, Alzheimer’s disease, and Parkinson’s disease and other age-related neurodegenerative conditions.

Does the 2025 award from BioTech Breakthrough indicate regulatory approval for KLTO therapies?

No; the award recognizes innovation and does not signify regulatory approval or commercial availability of therapies.

How might the BioTech Breakthrough award affect investor perception of KLTO stock (NASDAQ: KLTO)?

The award may boost visibility and perceived scientific validation, but it does not guarantee financial results or regulatory milestones.